Cisatracurium 200 mg vials recalled after subpotent stability assay results
Somerset Therapeutics is recalling 28,660 vials of Cisatracurium Besylate Injection, 200mg/20mL, after out of specification assay results during long term stability testing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Scored 2 under the rule that FDA Class III actions fall at 1 or 2: the record cites a subpotent assay result with no stated clinical consequence.
Plain-English summary
Cisatracurium Besylate Injection USP, 200mg/20mL (10mg/mL), supplied as 10 x 20 mL single-dose vials per carton, manufactured for Somerset Therapeutics, LLC of Hollywood, Florida, made in India, under NDC 70069-151-01, is being recalled.
The reason given in the enforcement record is a subpotent product: out of specification assay results observed during long term stability testing.
The recall covers 28,660 20mL vials from lot A250020, expiry 06/30/2026. Distribution was nationwide in the USA. The FDA has classified the action as Class III, its least serious category.
The record describes a specification failure rather than a reported patient harm. Facilities should quarantine the affected lot and follow the firm's instructions.
The recalled product
- Product
- CISATRACURIUM BESYLATE (CISATRACURIUM BESYLATE)
- Brand
- CISATRACURIUM BESYLATE
- Manufacturer
- SOMERSET THERAPEUTICS LLC
- Category
- Drug — Neuromuscular blocker
- Hazard
- subpotent
- stability-failure
- out-of-specification
- class-iii
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: A250020
- Exp Date 06/30/2026
UPCs (4)
- 0370069141014
- 0370069151013
- 0370069141106
- 0370069151105
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CISATRACURIUM BESYLATE
- ModerateCisatracurium 10 mg vials recalled after subpotent stability assay results
FDA (Drugs) · 2025-12-24
- ModerateCisatracurium 20 mg multiple-dose vials recalled after subpotent assay results
FDA (Drugs) · 2025-12-24
Same category
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- ModerateQuality Choice Earwax Removal Kit Carbamide Peroxide Subpotent Drug Recall
FDA (Drugs) · 2026-07-22
- ModerateFamily Wellness Carbamide Peroxide Earwax Removal Kit Subpotent Drug
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22